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Abstract: Carcinogenesis involves the inactivation or inhibition of genes that function as tumor suppressors. Deletions, 
mutations, or epigenetic silencing of tumor suppressor genes can lead to altered growth, differentiation, and apoptosis. 
DNA methylation and histone modifications are important epigenetic mechanisms of gene regulation and play essential 
roles both independently and cooperatively in tumor initiation and progression. Realization that many tumor suppressor 
genes are silenced by epigenetic mechanisms has stimulated discovery of novel tumor suppressor genes. One of the most 
useful of these approaches is an epigenetic reactivation screening strategy that combines treatment of cancer cells in vitro 
with DNA methyltransferase and/or histone deacetylase (HDAC) inhibitors, followed by global gene expression analysis 
using microarrays, to identify upregulated genes. This approach is most effective when complemented by microarray 
analyses to identify genes repressed in primary tumors. Recently, using cancer cell lines treated with a DNA methylation 
inhibitor and/or a HDAC inhibitor in conjunction with cDNA microarray analysis, candidate tumor suppressor genes, 
which are subject to epigenetic silencing, have been identified in endometrial, colorectal, esophageal, and pancreatic can-
cers. An increasing number of studies have utilized epigenetic reactivation screening to discover novel tumor suppressor 
genes in cancer. The results of some of the most recent studies are highlighted in this review. 
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INTRODUCTION 
Many cancers have been characterized by multiple ge-
netic and epigenetic alterations [1, 2]. In cancer cells, aber-
rant methylation of CpG islands has been found in the 5’ end 
of the regulatory regions and/or the first exons of tumor sup-
pressor genes and genes responsible for genomic stability [3, 
4]. Epigenetic changes can silence the transcription of these 
important genes, leading to clonal proliferation of tumor 
cells [3, 4]. Epigenetic modifications of cytosine residues in 
DNA and the NH2 termini of histone proteins have emerged 
as key mechanisms in chromatin remodeling, affecting tran-
scriptional regulation. Growing evidence exists that interplay 
occurs between cytosine methylation and histone modifica-
tion. The methyl-CpG binding protein, MeCP2, has been 
found to be associated with histone deacetylase (HDAC) 
activity, providing a pathway by which histone modification 
can be induced by DNA methylation changes [4-6]. The 
identification and characterization of genes whose CpG is-
lands in the promoter are selectively hypermethylated in can-
cers not only improves our understanding of the role of 
epigenetic alterations in tumorigenesis but may also lead to 
the discovery of novel tumor suppressor genes. Recently, 
using cancer cell lines treated with a DNA methylation in-
hibitor and/or a HDAC inhibitor in conjunction with cDNA 
microarray analysis, candidate tumor suppressor genes, 
which are subject to epigenetic silencing, have been identi- 
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fied in endometrial [2], colorectal [7], esophageal [8], and 
pancreatic [9] cancers. 
ENDOMETRIAL CANCERS 
Takai et al. [2] used the cDNA microarray technique to 
identify genes significantly (P < 0.05) up-regulated in an 
endometrial cancer cell line, Ishikawa, after treatment with 
5-aza-2’-deoxycytidine (5-Aza-CdR; 3 days), which blocks 
DNA methylation, and suberoylanilide bishydroxamide 
(SAHA; 1 day) to inhibit HDAC. The gene expression pro-
file was compared before and after treatment using Af-
fymetrix (Santa Clara, CA) human genome U133A microar-
ray chips containing 22,283 transcripts (Fig. 1). Treatment 
with these agents resulted in up-regulation (defined as a 
2.0-fold increase) of 676 genes. They focused on 101 genes 
that were either not expressed or expressed only at low levels 
(raw values <500) before treatment of the cell line. To nar-
row further the list of candidate genes, they queried their 
expression status in six endometrial cancer samples as de-
termined by microarray analysis. The clinical samples were 
individually analyzed by microarray. Thirty-six of the 101 
genes were expressed at very low levels in the clinical cancer 
samples. The 5’ regulatory regions of these genes were ana-
lyzed in the BLAST database and the CpG Island Searcher 
[10] to determine whether they contained CpG islands. 
Thirty-two of the 36 (89%) genes harbored CpG sites in the 
promoter region. 
Expression of these 36 genes was examined in six endo-
metrial cancer cell lines, including Ishikawa, with or without 
5-Aza-CdR and SAHA using real-time quantitative reverse  
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Fig. (1). Outline of selection of tumor suppressor genes in endo-
metrial tissue. 
transcription-PCR (RT-PCR). The Tig1 and C/ebpa genes 
were completely silenced in all six endometrial cancer cell 
lines, and their expressions were induced in each cell line 
after exposure to 5-Aza-CdR and SAHA. 
Expression of both genes was low in endometrial cancer 
cell lines and clinical samples but high in normal endo-
metrial tissues. Bisulfite sequencing, restriction analysis, 
and/or methylationspecific PCR revealed aberrant methyla-
tion of the CpG island in the Tig1 gene of all 6 endometrial 
cancer cell lines examined and 4 of 18 clinical endometrial 
cancers, whereas the C/ebpa promoter remained unmethy-
lated in endometrial cancers. Chromatin immunoprecipita-
tion showed increased acetylated histone H3 bound to both 
Tig1 and C/ebpa genes after treatment with 5-Aza-CdR 
and/or SAHA. Forced expression of either TIG1 or C/EBP 
led to significant growth reduction of Ishikawa cells (Fig. 2). 
Their data suggest that TIG1 or C/EBP function as tu-
mor suppressor proteins in endometrial cancers and that their 
reexpression may be a therapeutic target. 
COLORECTAL CANCERS 
Suzuki et al. [7] used cDNA microarray technology to 
identify genes upregulated in the colorectal cancer (CRC) 
cell line RKO, after cells were treated with low-dose 5-Aza-
CdR, which minimally blocks DNA methylation, and 
trichostatin A (TSA) to inhibit HDAC. Of a total of 10,814 
genes examined by subtraction microarray, 74 were upregu-
lated by treatment with 5-Aza-CdR and/or TSA. Of all of the 
non-EST (expressed sequence tags) genes, 56 had known 
chromosomal positions. They were also able to identify 5' 
CpG islands (GC content <60%, ratio of CpG to GpC <0.6 
and minimum length 200 bp) for 27 of the 56 genes. 
Their findings suggested that SFRP1,  SEZ6L,  CXX1, 
KIAA0786, S100A10 and TIMP2 might influence tumor de-
velopment and progression. They therefore studied these 
genes in tumor cell lines of other types of cancer. A pattern 
of tumor profiling emerged: complete hypermethylation of 
SFRP1, SEZ6L, LPPH1 and CXX1 was common in CRC and 
gastric cancers, but only partial or no methylation was seen 
in all other types of cancer studied. They found exceptions to 
this pattern for SFRP1. This gene has been shown to induce 
apoptosis in a breast cancer cell line, MCF7, which did not 
express the gene in the basal state [11]. They found complete 
methylation of the CpG island region in this cell line, as well 
as in MDA MB231 breast cancer cells and two of four pros-
tate cancer cell lines studied. 
ESOPHAGEAL CANCERS 
Yamashita et al. [8] performed a comprehensive survey 
of commonly inactivated tumor suppressor genes in eso-
phageal squamous cell carcinoma (ESCC) based on func-
tional reactivation of epigenetically silenced tumor suppres-
sor genes by 5-Aza-CdR and TSA using microarrays con-
taining 12,599 genes. Among 58 genes identified by this 
approach, 44 (76%) harbored dense CpG islands in the pro-
moter regions. Thirteen of twenty-two tested gene promoters 
were methylated in cell lines, and ten in primary ESCC ac-
companied by silencing at the mRNA level. Potent growth 
suppressive activity of three genes including CRIP-1, Apol-
ipoprotein D, and Neuromedin U in ESCC cells was demon-
strated by colony focus assays. 
PANCREATIC CANCERS 
To identify potential targets for aberrant methylation in 
pancreatic cancer, Sato et al. [9] analyzed global changes in 
gene expression profiles of four pancreatic cancer cell lines 
after treatment with the demethylating agent 5-Aza-CdR 
and/or the histone deacetylase inhibitor TSA. A substantial 
number of genes were induced 5-fold or greater by 5-Aza-
CdR alone (631 transcripts), TSA alone (1196 transcripts), 
and by treatment with both agents (857 transcripts). Four 
hundred and seventy-five genes were markedly (>5-fold) 
induced after 5-Aza-CdR treatment in pancreatic cancer cell 
lines but not in a nonneoplastic pancreatic epithelial cell line. 
The methylation status of 11 of these 475 genes was exam-
ined in a panel of 42 pancreatic cancers, and all 11 of these 
genes were aberrantly methylated in pancreatic cancer but 
rarely, if any, methylated in 10 normal pancreatic ductal epi-
thelia. These genes include UCHL1 (methylated in 100% of 
42 pancreatic cancers), NPTX2 (98%), SARP2 (95%), 
CLDN5 (93%), reprimo (86%), LHX1 (76%), WNT7A 
(71%), FOXE1 (69%), TJP2 (64%), CDH3 (19%), and ST14 
(10%). Three of these 11 genes (NPTX2,  SARP2, and 
CLDN5) were selected for further analysis in a larger panel 
of specimens, and aberrant methylation of at least one of 
these three genes was detectable in 100% of 43 primary pan-
creatic cancers and in 18 of 24 (75%) pancreatic juice sam-
ples obtained from patients with pancreatic cancer. Thus, a 
substantial number of genes are induced by 5-Aza-CdR 
treatment of pancreatic cancer cells, and many of them may 
represent novel targets for aberrant methylation in pancreatic 
carcinoma. 24    Current Genomics, 2008, Vol. 9, No. 1  Takai and Narahara 
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Fig. (2). Enforced expression of either Tig1 or C/ebpa suppressed clonogenic growth of Ishikawa cells. Ishikawa endometrial cancer cells 
were transfected with either pcDNA3.1 (Empty vector), pcDNA3-FLAG-Tig1 (TIG), or pcDNA3-C/ebpa (C/EBP). Protein expression lev-
els at 24 hours after transfection were confirmed by Western blot using either anti-FLAG or anti-C/EBP antibody (A and D). Transfected 
cells were selected with G418, and resistant colonies (after 14 days of culture in G418) were stained with crystal violet (B and E). The num-
bers of the colonies were counted (C and F). Columns, mean of experiments repeated thrice with triplicate dishes per experimental point; 
bars, SD. 